Evidence map›Paper›PMID 42360329›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Mariola Zapater-Fajari, Marco Bucci, Konstantinos Chiotis, Ove Almkvist, Anders Wall, Jonas Eriksson, Gunnar Antoni, Ilaria Pola, Kübra Tan, Wiebke Traichel and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mariola Zapater-Fajari *Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden.
Marco Bucci *Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden.
Konstantinos ChiotisDepartment of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden.
Ove AlmkvistDepartment of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden.
Anders WallDepartment of Surgical Sciences, Section of Molecular Imaging & Medical Physics, Uppsala University, Uppsala, 75185, Sweden.
Jonas ErikssonPET Centre, Uppsala University Hospital, Uppsala, 75185, Sweden.
Gunnar AntoniPET Centre, Uppsala University Hospital, Uppsala, 75185, Sweden.
Ilaria PolaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Kübra TanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Wiebke TraichelDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Andrea L BenedetDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Nenad BogdanovicDepartment of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden.
Agneta NordbergDepartment of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Neo 7th Floor, Stockholm, 14183, Sweden. agneta.k.nordberg@ki.se.ORCID http://orcid.org/0000-0001-7345-5151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to compare regional brain tau extent across the disease spectrum in early- and late-onset Alzheimer's disease using the second-generation tau PET tracer [

methodsWe examined 57 participants: 39 patients from the Cognitive Assessment Unit at Karolinska University Hospital (Stockholm/Sweden)-diagnosed as MCI Aβ- (n = 10), MCI Aβ + (n = 16; 8 EO and 6 LO), and AD (n = 13; 5 EOAD and 8 LOAD)-and 18 cognitively normal controls. All participants underwent [

resultsBoth EO and LO MCI (Aß +) showed higher [

conclusions[

Indexed as

Alzheimer DiseaseCognitionPositron-Emission Tomographytau ProteinsAgedAge of OnsetAtrophyBrainFemaleHumansMaleMiddle Agedtau ProteinsAlzheimer’s disease biomarkersBlood-based biomarkersCognitionNeurodegenerationNeurofibrillary tau tanglesPositron emission tomography (PET)

Identifiers

PMID42360329
PMCPMC13633377

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.